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Simulated pathogenesis of severe acute respiratory distress
syndrome and leukopenia induced with inuenza A/H5N1
virus infection and its treatment with immunoglobulins
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Abstract. Background: Severe acute respiratory distress syndrome
(ARDS) is a major symptom of infection with inuenza A/H5N1virus. Pa-
tients with inuenza A/H5N1 suer from leukopenia, which is regarded as a
prognostic factor of cellular injury associated with ARDS. Nevertheless, the
association of cellular injury with leukopenia remains unclear.
Methods and ndings: A within-host mathematical model, a system of delay
dierential equations of virus dynamics and immune response, was applied to
ascertain inuenza pathogenesis. When leukocytes destroy infected cells, the
ratio of leukocyte destruction becomes higher in the case of A/H5N1. More-
over, a comparison of therapies for leukopenia using the model reveals that
immunoglobulin therapy is more eective than neuraminidase therapy.
Conclusion: Simulations show that the increased ratio of destruction of leuko-
cytes induces leukopenia and cellular injury of A/H5N1. Furthermore, results
of simulations demonstrate the possibility of immunoglobulin therapy for treat-
ing leukopenia associated with inuenza A/H5N1.
1. INTRODUCTION
Emerging inuenza, especially A/H5N1, is a threat to society. The inuenza
A/H5N1 pathogenesis must be elucidated, but the peculiar pathology of A/H5N1
remains unclear. Patients infected with inuenza virus A/H5N1 become severely
ill, exhibiting severe acute respiratory distress syndrome (ARDS) and leukopenia
[1]. Patients with inuenza A/H5N1 in Vietnam reportedly have fever, respira-
tory symptoms, and leukopenia [2]. Extraordinary cellular injury of the lung and
leukopenia were also reported in a case in Thailand [3]. However, the association
of cellular injury with leukopenia remains obscured.
In cases where etiological data related to infection with inuenza A/H5N1 virus
are limited, mathematical models can be useful to ascertain the pathological pro-
cess within a host [4{7]. Various within-host models, from simple to complex,
have been proposed for inuenza [8{13]. To ascertain the pathological process of
infectious disease, latency is important. Two methods are used to simulate latency;
adding ordinary dierential equations of the intermediate state to the model with
89
????????????????????????????????????????????????????????????? ??????????????????????? ??
90 H. YASUDA, S. KAWACHI, K. SUZUKI
new parameters or simply using delay dierential equation [5, 16]. Simple model
is suitable to analyze the A/H5N1 pathology because identifying many parame-
ters of complex models is dicult [14, 15]. For simple simulations of pathology
with latency, models including delay dierential equations have been exploited by
Marchuk [16].
The following ndings are our point of departure. Type II alveolar epithelial
cells are the prime targets of inuenza A/H5N1 [17]. The model mouse for ARDS,
which is induced with inuenza virus PR-8 A/H1N1, shows destruction of lung
tissues after 7 days post infection (dpi) followed by invasion of neutrophils and
macrophages into alveolar lavage [18]. Based on our clinical observations in cases
of A/H5N1 where white blood cell (WBC) counts are a prognostic factor of cellular
injury of the lung in patients, we infer that neutrophils and macrophages invade into
alveolar lavage also in cases where A/H5N1 plays an important role in pathogeny
[1]. The fraction of macrophages and neutrophils in WBC of infected mouse is
approximately 0.95. That of lymphocytes is 0.05 [19]. However, in preceding
studies, mainly of seasonal inuenza, lymphocytes { T-cells, B-cells and plasma
cells { are modeled as constituting the immune response system [16].
Furthermore, for seasonal inuenza, neuraminidase (NA) inhibitor reduces the
length of illness of patients by 1-2 days when they are treated 36-48 h from the
onset of symptoms [20]. As described elsewhere in the literature, ve Vietnamese
patients infected with A/H5N1 were treated with NA inhibitor started after 5-12
dpi: one recovered, one was recovering, and three died [2]. For mice infected with
A/H5N1, NA inhibitor is reportedly ecacious when therapy is initiated after 24 h
or 36 h, but all mice die when treatment is delayed to 48 h [21]. Moreover, an NA
inhibitor-resistant virus of A/H5N1 has been detected [22]. Alternative treatment
should be prepared in cases where NA inhibitor is not ecacious.
In this study, proles of WBC are modeled as a pathogenic factor of A/H5N1.
Using the model, the possibility of therapy with NA inhibitor or immunoglobulins
for inuenza A/H5N1 is estimated.
2. METHODS
2.1. Within-host model of inuenza
The lungs are modeled as the target organ of infection. For A/H5N1, in the
human cases in Vietnam, A/H5N1 virus antigens were detected predominantly in
lung tissues [17]. In the case of mice, inuenza A/H5N1 virus titers in the lung
were found to be much greater than those in the brain, spleen, liver, heart, blood, or
kidney [23,24]. Furthermore, damage of lung epithelial cells is grave when seasonal
inuenza becomes severe [25]. Here, virus dynamics in epithelial cells of the lung
and immune responses are modeled using the following delay dierential equation
systems; modifying Marchuk's model to simulate the pathology of A/H5N1[8,16].
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Virus dynamics in epithelial cells
dT
dt
=  TV + g (T; I) ; (1)
dI
dt
= T (t  )V (t  )  II   IL; (2)
dV
dt
= I   V V   FV: (3)
Immune response system
dM
dt
= MV   MM; (4)
dL
dt
= M (t  M )L (t  M )  L (L  L)  IL; (5)
dF
dt
= L  FV   FF: (6)
In those equations, T represents the fraction of the susceptible type II alveolar
epithelial cells in the lung, i.e. target epithelial cells. I stands for the share of
infected cells in the lung. V denotes the relative number of virus titer normalized
by a reference value in the lung tissue. M denotes the relative number of antigen-
presenting cells. L represents the relative number of activated WBCs in peripheral
blood. Furthermore, F is the relative number of antibody titer. Parameter M
represents naive antigen-presenting cells; L is the equilibrium value of precursor
of WBC. They are assumed as constant values. Variable t denotes time; ? and
M are time lags. Other variables are I , V , M , L, and F , which are the
rate constants, and coecients , , , , , , , , and , which are the model
parameters described in section 2.2. Finally, g is a function of cell regeneration in
the lung.
The equations govern the following phenomena. Target epithelial cells (T ) are
infected by inuenza viruses (V ). They then turn into infected cells (I) with time
lag ?. Infected cells die at a constant rate or are destroyed by WBC (L). Viruses
are produced in the infected cells, die at a constant rate, or are neutralized by
antibody (F ). Furthermore, the lost target cells are recovered through regener-
ation of the lung. Regarding the immune system, naive antigen-presenting cells
(M) in the peripheral blood are stimulated by the inuenza virus and become
antigen-presenting cells (M). WBCs, which are multiplied by antigen-presenting
cells with time lag M , decrease to an equilibrium value (L
) at a constant rate.
The WBCs are destroyed with ratio ? when destroying infected cells. Antibodies
are produced in WBC. They die at a constant rate or are consumed with ratio ?
when neutralizing the virus.
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During the recovery phase of infection, damaged lung regeneration occurs
rapidly [25]. Regeneration is modeled as a linear function of T [4, 11] or as a
quadratic function [10]. Here, all the regenerated cells are assumed to be suscepti-
ble, although the susceptibility of regenerated cells remains unclear. The function
below is used in equation (1).
g (T; I) = ! (1  T   L)  Tn (7)
Here, ? and ? are parameters; n is the growth index. The growth rate of cells is
Tn. In addition, !(1  T   I) is the rate of dead cells to be replaced when cured.
2.2. Parameters of the model
Rate constants and the parameters are tted to simulations, as referred from
acceptable ranges in preceding studies.
2.2.1 Rate constants
The tted values and acceptable ranges of rate constants are following. The rate
constants and time lags are I = 0:021, V = 0:083, M = 0:042, F = 0:0018
(1/h),  = 3, M = 9:6 (h). The acceptable ranges of destruction of infected cells
because of cytopathicity I is 0.021-0.083 (1/h) [16] and 0.055-0.086 (1/h) [26].
The rate constant of removal of antigen particles naturally by the immune system
V is 0.083-0.167 (1/h) [16], or the loss of infectivity is 0.105 (1/h) [26]. The
rate constant of loss of stimulated antigen-presenting cells M is 0.042-0.063 (1/h)
[16]. The rate constant of natural death of antibodies F is 0.0018 (1/h) [16].
Furthermore, the time lag of infection  is 1.2-6 (h) [26]. For M , the duration of
lymphocyte cell division is 9.6-24 (h) [16] or 12 (h) [8]. No data are available in the
literature for the loss rate of whole WBC L. Instead of WBC as a whole, referring
to the acceptable range of the rate constant of lymphocytes [16], loss of T-helper
for CTL is 0.03-0.05 (1/h), loss of T-helper for B-cells 0.03-0.05 (1/h), natural
death of CTL 0.01-0.02 (1/h), natural death of B-lymphocytes 0.002-0.004 (1/h),
natural death of plasma cells 0.01-0.02 (1/h). The specied value is L = 0:007
(1/h).
2.2.2 Parameters
Parameters in the model are normalized using reference values. The infection rate
? specied in the model is 0.00035 (1/h). The virus product rate ? is 120 (1/h).
The ranges of? and? are described below. When the initial virus load is 3:2106,
1104, 4102, 1102 in units of 50 % egg infectious dose (EID), the corresponding
infection rates ? are 8:6 10 9, 2:6 10 9, 1:1 10 5, 6:3 10 8 (1/(EID day))
[4]. Using 105 (EID) as the reference value, ? is in the range of 1:1 10 6  0:046
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(1/h). For parameter ?, the corresponding values are 2:8 10 3, 1.4, 1.5, 5:5 10
(EID/day) [4]. Normalizing by the 105 (EID) and the number of initial target cells
7 109 , the range of ? is 8.2-1:6 105 (1/h).
The index of growth is set as n = 1. The acceptable range is 2/3-1, as described
in an earlier report [27]. The recovery rate of susceptible cells ! is specied as
0.0035 (1/h) to reproduce the experiment of mice infected with H1N1 inuenza
virus, which shows the peak of viral load at 4 dpi and the peak of lung damage at
11 dpi, with recovery at approximately 21 dpi [25].
The range of rate of antigenic stimulation to WBCs, ?, is 1011   4  1016
(ml/(mol day)). The range of M is 510 19 310 18 (mol/ml) [16]. Then the
product M is in 2 10 9  5 10 3 (1/h). The specied value is M=0.00015
(1/h).
The production rate of activated WBC: ? is specied ?=0.25 (1/h) based on
the following. The number of cytotoxic T lymphocyte (CTL) creation by division
2-4 and rate of stimulation for CTL is 51037 71039((ml2/(mol2 day)), that of
B-cell is (1 100)1037 ((ml2/(mol2 day)) and the range of naive antigen-presenting
cells is 510 19 310 18 (mol/ml), specic precursor of CTLs is (1 10)10 19
(mol/ml) and specic precursor of B-lymphocytes is 510 20 510 19 (mol/ml)
[16]. Using the reference value of antigen presenting 10 19(mol/ml), lymphocytes
10 18 (mol/ml), the range of production rates is 0:06   116:6 (1/h). Here the
equilibrium value of precursor is specied as L = 0:1.
The rate of synthesis of antibodies,?, is specied as?=0.4 (1/h) based on the
following. The range of rate constant for synthesis of IgG molecules by one plasma
cell is 8:5107 1:7108 (molecule /(cell day)) [16]. Setting the reference value of
antibodies 1013 (molecule/ml) and using the referred value of lymphocytes 10 18
(mol/ml), parameter ? is between 0.21-0.43 (1/h).
The rate constant of antibodies neutralizing antigen: ? is specied as 6.1, which
is adopted from a dierent normalized model based on Marchuk's model [10]. The
ratio of destruction of antibodies ? when neutralizing viruses is specied as 10.
The ratio of IgG molecules to neutralize viral particles is 1-10 [16].
The literature has no data available for the rate of destruction of infected cells by
WBCs,?, and the ratio of destruction of WBCs when destroying infected cells,?.
In earlier studies, lymphocytes were shown to destroy infected cells for the seasonal
case [16], but neutrophils and macrophages are regarded as playing an important
role for A/H5N1 [18]. Furthermore, parameters ? and ? dier for those cases.
The tted values of? are 2.5 (1/h) for the seasonal case and 3.6 (1/h) for A/H5N1.
Furthermore, ?=0.01 is used for seasonal inuenza. For A/H5N1, the tted value
is ?=0.175 (1/h). The values of ? and ? are tted without information related
to the acceptable range. For tting, the parameters are specied to reproduce
the cellular injury of ARDS in case of seasonal inuenza or severe ARDS in case of
A/H5N1. For ARDS, international standards [28] involve the acute onset P/F ratio
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(Partial pressure of oxygen in arterial blood/ Fraction of oxygen in the space being
measured) <200 mmHg. The P/F ratio <100 mmHg is used for severe ARDS,
with the fact that the P/F ratio in case of A/H5N1-positive case in Vietnam is
61.4 ? 59.3 mmHg [1]. Usually, a P/F value higher than 450 mmHg is regarded
as normal. Here, simply assuming cellular injury is proportional to P/F ratio, the
values 200/450= 0.44 and 100/450=0.22 are adopted, respectively, for the criteria
of ARDS and severe ARDS. In tting, the fraction of susceptible cells must be less
than the criterion.
Next the parameters are summarized. Two parameters dier: ?=2.5 (1/h), ?
=0.01 for severe seasonal inuenza and ?=3.6 (1/h), ?=0.175 for A/H5N1. The
other parameters are common for both cases: I = 0:021 (1/h), V = 0:083 (1/h),
M = 0:042 (1/h), F = 0:0018 (1/h), L = 0:007 (1/h),  = 3 (h), M = 9:6
(h) and ?=0.00035 (1/h), ?=120 (1/h), ?=6.1 (1/h), M = 0:00015 (1/h), ?
=0.25 (1/h), ?=0.4 (1/h), ! = 0:0035 (1/h), ?=10, and L=0.1. The param-
eters, adopted from dierent reports and interchangeable, might be unsuitable for
quantitative research. However, the aim of this model is to ascertain the causes of
leukopenia and its association with cellular injury of severe ARDS.
2.3. Initial conditions and numerical methods
As initial conditions, the inuenza virus invades human organs at t=0, no virus
was present in the organ earlier. The state of the system is T = 1:0, I = 0:0,
V = 0:0, M = 0:0, L = 0:1, F = 0:0 before t = 0. At t = 0, V = 1:0 is added
to variable V . For V = 1:0 corresponding to 105 (EID), substantial invasion of
the virus into the target organ is assumed to simulate severe infection. The initial
virus invasion is described as occurring between 102 3:2106 (EID) by Handel et
al. [4]. The duration of simulation is three weeks. The conventional fourth-order
Runge-Kutta method is used for calculation. The time step width of simulation is
1 s because the delay dierential equations of immune response become known as
a sti equation [29].
2.4. Therapy eect of NA inhibitor and immunoglobulins
The model is used to estimate the eectiveness of NA inhibitor therapy and
immunoglobulin therapy for A/H5N1. Modication of the model to include the
eects of both therapies is the following. NA inhibitor reduces the progeny virus
yield in the infected cells, as described in an earlier report [30]. Equation (3) is
modied to include the eect of NA inhibitor.
dV
dt
= (1  " (t))I   V V   FV (8)
Here, "=0, t < Tm, "? "0, t > Tm, where Tm is the time at which the treatment
starts. "0 represents the ecacy of NA inhibitor, which is specied as 0.98 [30].
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However, immunoglobulin inhibits intracellular neutralization rather than yield
reduction [31]. Equations (1) and (2) are modied to include the eects of im-
munoglobulin as shown below.
dT
dt
=   (1  " (t))TV + g (T; I) ; (9)
dI
dt
= (1  " (t))T (t  )V (t  )  I   IL: (10)
Here, " is the same function as (8).
The ecacy of immunoglobulin is unclear [32]. Therefore, the ecacy is inferred
as 0.8 based on those of other inammatory diseases [33].
3. RESULTS
3.1. Virus titer and infected epithelial cells in lung
The cases of inuenza A/H5N1 and seasonal inuenza are compared in Figs.
1 and 2. Relative changes of the portion of susceptible epithelial cells (T ), the
number of infected epithelial cells (I) and virus titer (V ) in lung tissue are shown
respectively in Figs. 1A, 1B, and 1C. In simulations, the lowest fraction of sus-
ceptible cells was approximately 0.32 for the seasonal case and approximately 0.1
for A/H5N1. For seasonal inuenza, the peak of the virus number appeared at
approximately 6 dpi. Using the normalization factor of 105 (EID), the amount
of virus in the seasonal case was 104   106 (EID) (Fig. 1C). It was in the order
explained by Handel et al. [4]. For A/H5N1, the peak of the virus number was
delayed and was higher.
3.2. Immune response to infection with inuenza virus
The relative change of WBC counts (L) in the peripheral blood normalized to
the equivalent value (L), antigen-presenting cells (M), and the relative antibody
titer (F ) are presented respectively in Figs. 2A, 2B, and 2C. The changes of
WBC counts in peripheral blood revealed dierent proles in the respective cases
of seasonal and A/H5N1 inuenza. For the seasonal case, the peak of the WBC
count was at approximately 10 dpi (Fig. 2A); antibodies appeared after 15 dpi
(Fig. 2C), showing the recovery of susceptible cells started after 9 dpi (Fig. 1A).
However, for A/H5N1, WBC counts decreased. The appearance of antibody and
the recovery of susceptible cells was delayed.
3.3. Eects of parameter ? and ? on the severe ARDS
To clarify the respective roles of parameters ? and ?, simulations are per-
formed ? ranging from 0.01 to 0.2 with xed ?=3.6 and ? ranging from 2.25 to
3.9 with ?? 0.175 xed. Results of susceptible epithelial cells in lung (T ) were
as depicted in Fig. 3. The fraction of susceptible cells decreased from the level at
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Figure 1. Virus dynamics in epithelial cells in lung infected with in-
uenza virus of A/H5N1 and seasonal type: A, Relative change of sus-
ceptible epithelial cells (T ); B, Relative change of infected epithelial
cells (I); C, Relative virus titer (V ) in lung tissue.
which ARDS did not occur to the level of severe ARDS when ? increased with
xed ? (Fig. 3A). However, as Fig. 3B shows, irrespective of ?, the minimum
of susceptible cells of all cases maintained ?=0.175, reaching the level of severe
ARDS. Furthermore, for increasing ?, the minimum value of susceptible cells in-
creased because more infected cells were destroyed by increasing ?. Moreover, the
production of viruses was suppressed.
3.4. Eects of parameters ? and ? on leukopenia
The results of WBC counts in peripheral blood (L) of the parameter runs are
shown in Fig. 4. As portrayed in Fig. 4A, leukopenia did not occur for ?=0.01,
but increasing ? decreased WBCs and caused leukopenia. Furthermore, as shown
in Fig. 4B, irrespective of the value of ? when maintaining ?=0.175, leukopenia
occurred. Figures 3 and 4 clearly show that parameter ? plays an important role
in leukopenia and cellular injury with A/H5N1.
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Figure 2. Immune responses in the peripheral blood to infection with
inuenza virus of A/H5N1 and seasonal type: A, Relative change of
white blood cell counts (L); B, Relative number of antigen-presenting
cells (M); C, Relative antibody titer (F ).
3.5. Therapies with NA inhibitor and immunoglobulins
The model shows therapeutic eects of NA inhibitor and immunoglobulins and
recovery from infection with A/H5N1, as presented in Fig. 5. The changes of
the target epithelial cells (T ) in lung, virus tissues (I), and WBC counts (L) are
presented, respectively, in Figs. 5A, 5B, and 5C, showing that both therapies were
ecacious on recovery, but with some dierences in their eects. The virus titer in
the treatment with NA inhibitor was reduced faster than that with immunoglob-
ulins (Fig. 5B). However, the recoveries of susceptible cells and WBC counts by
immunoglobulin treatment occurred more rapidly than those with NA inhibitor
(Figs. 5A, 5C).
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Figure 3. Relative change of susceptible epithelial cells in lung. Param-
eter ? is the rate of destruction of infected cells by WBCs. Parameter
? is the ratio of destruction of WBCs when destroying infected cells. A:
?=0.01-0.2 and ?=3.6. B: ?=2.25-3.9 and ?=0.175. Case in which
?=0.175 and ?=3.6 are the same as those for A/H5N1 in Figs. 1A.
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Figure 4. Relative change of leukocytes in peripheral blood. Parameter
? is the rate of destruction of infected cells by WBCs. Parameter ?
is the ratio of destruction of WBCs in turn when destroying infected
cells. A: ?=0.01-0.2 and ?=3.6. B: ?=2.25-3.9 and ?=0.175. Case
in which ?=0.175 and ?=3.6 are the same as those for A/H5N1 in
Figs. 2A.
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Figure 5. Treatment of neuraminidase inhibitor and immunoglobulins
for A/H5N1: A, Relative change of susceptible epithelial cells (T ) in
lung; B, Relative change of virus tissues(V ); C, Relative WBC counts
(L). Treatment started after 4-12 dpi in Fig.5.
4. DISCUSSION
4.1. Proles of symptoms after infection with inuenza A/H5N1
Our simulations conrmed the course of viral titer and antibody production in
patients infected with seasonal or A/H5N1 inuenza, and reproduced symptoms
for A/H5N1 delayed in comparison to those of seasonal inuenza. The simulation
showed a peak of viruses as 6 dpi, with existence until 12 dpi. For the actual course
of seasonal infection, the virus peak comes on 3 dpi [30, 34]. A separate report
describes that viruses peak at 5 dpi and exist until 10 dpi [13]. Furthermore, the
peak of antibodies occurs at around 11 dpi [35]. In addition, an experiment with
mice infected with H1N1 inuenza virus shows the viral load peak at 4 dpi and
lung damage at 11 dpi [25].
The real courses of A/H5N1 have been reported as follows. The latent period of
A/H5N1 is usually 2-5 days [32]. The peak of A/H5N1 virus titer in the patients
is apparent at 6 dpi and remains high at 8 dpi. Viral titer in the lung of a mouse
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infected with A/H5N1 is high during 1-7 dpi, showing the peak at 6 dpi and a
subsequent decrease to the level of detection on 8 dpi [36]. Moreover, antibody
titer of A/H5N1 in plasma is not detected during 7 dpi, but is detected in 70% of
patients in the second week, and in 80% in the third week, showing a peak at 2-10
weeks [37].
For the simulated A/H5N1, the virus titer peak was revealed by approximately
12 dpi in the present study. Antibodies appeared in the simulations at 19 dpi:
after viruses had disappeared. The peak of viruses and the appearance of antibody
in case of A/H5N1 infection were delayed compared to that of seasonal inuenza
in both real and simulated cases. In our simulations, the change of symptoms of
A/H5N1 was attributable to two parameters: ? and ?. When ? was increased,
the delay of the cellular injury and leukopenia appeared because the increased
? showed reduction of both the number of infected cells and WBC destruction.
Results show that reduction of the infected cells decreased production of virus and
the spread of the infection. However, changing parameter ? showed only a small
eect on delay in this study. Simulations showed that the increase of destruction
of infected cells by WBCs caused a delay of symptoms during A/H5N1 infection.
4.2. Cellular injury and leukopenia
Leukopenia, the characteristic feature of A/H5N1 infection, is associated with
cellular injury of ARDS [1]. However, the cause of leukopenia has remained un-
clear. In the Vietnam cases, infected patients with A/H5N1-positive or A/H5N1-
negative including infection with rhinovirus, adenovirus and/or bacteria showed
severe ARDS. However, only the A/H5N1-positive patients showed leukopenia [1].
In the Thailand cases, WBC counts of fatal A/H5N1 patients were approximately
half those of non-fatal A/H5N1 patients. All fatal A/H5N1 patients need treatment
in ICU because of ARDS, but non-fatal patients infected with A/H5N1 did not [3],
showing that ARDS and leukopenia are tightly associated in cases of A/H5N1. Re-
garding the cause of leukopenia, the infected model mouse for ARDS shows severe
pneumonia with leukocyte inltration into alveolar lavage [18]. In our simulations,
leukopenia was shown for ?>0.01, but not for ?=0.01. Furthermore, leukopenia
occurred irrespective of the value of ?, indicating that parameter ? is the key to
leukopenia. WBC counts are reduced in equation (5) if ? becomes large. Further-
more, antibodies in equation (6) decreased, and viruses increased in equation (3).
Viruses also increased because of the decrease of the destruction of infected cells
by WBCs in equation (2). More viruses infect more susceptible cells into infected
cells. The infected cells were destroyed or died in this study. Therefore, parameter
?, if large, can allow leukopenia and cellular injury to occur simultaneously. For
that reason, the degrees of leukopenia and ARDS are closely mutually associated.
Our results show that the increased ratio of destruction of WBCs interacting with
infected cells is the cause of leukopenia in cases of A/H5N1.
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4.3. Therapeutic eect of NA inhibitor or immunoglobulins
Finally, we conducted simulations to compare NA inhibitor therapy and im-
munoglobulin therapy with cases of infection with A/H5N1. The simulated treat-
ments started after 4-12 dpi because the median duration from onset to hospital
admission was reported as 5.9 days in Vietnam [2], as 4 days in Thailand [3], and as
3 days in Taiwan [38]. Furthermore, treatment with NA inhibitor started after 5-12
dpi was reported [2]. Antiviral treatment using NA inhibitor is recommended for
A/H5N1, but NA inhibitor resistance can emerge [22]. Some alternative treatment
should be prepared. Monoclonal antibody is a candidate [39]. Another candidate
is immunoglobulins [40,41]. Immunotherapy using convalescent plasma shows e-
cacy after NA inhibitor has lost ecacy [42]. The cells of mice are protected from
A/H5N1 infection by treatment with immunoglobulins [43]. Furthermore, although
few patients have been treated with immunotherapy and although treatments were
uncontrolled including antivirals, the investigation of immunotherapy used against
A/H5N1 should be encouraged [32]. Our simulations showed that NA inhibitor
and immunoglobulin therapies have equivalent ecacy against A/H5N1. Compar-
ing the results of two therapies in our simulation, the viruses in the treatment
with NA inhibitor were reduced more rapidly than those with immunoglobulins
because NA inhibitor suppressed the virus production rst in the model. However,
the recovery of susceptible cells by immunoglobulin treatment was faster than with
NA inhibitor because immunoglobulins rst change susceptible cells into infected
cells. Furthermore, the recovery of WBCs by treatment with immunoglobulins was
faster than that by treatment with NA inhibitor. The reason in the model is the
following. With NA inhibitor treatment, the yield of viruses decreased rst. Then
infected cells decreased over time. The decreased destruction of WBCs followed. In
addition, with the decreasing viruses, stimulation of antigen-presenting cells and
the production of WBCs decreased. However, with immunoglobulin treatment,
infected cells were reduced rst; then the destruction of WBCs decreased. Con-
sequently, the recovery by treatment with immunoglobulins might be faster than
that by treatment with NA inhibitor. Results of our simulations suggest that im-
munoglobulins are more eective than NA inhibitor for leukopenia, especially in
cases where treatment has been delayed.
4.4. Conclusions
Simulations in cases of infection with A/H5N1 virus show that increased de-
struction of WBCs interacting with infected cells caused leukopenia and cellular
injury. Furthermore, simulation results showed the possibility of immunoglobulin
therapy for leukopenia caused by inuenza A/H5N1.
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